Education Library

A heparin-free purge alternative, sodium-bicarbonate, is now approved for certain patients, enabling simpler anticoagulation management and reduced heparin-related risks.

A Heart Team approach and hemodynamic assessment led to timely and effective use of Impella 5.5 with SmartAssist for this patient with PCCS.

Claudius Mahr, DO, discusses outcome differences between patients with acute de novo cardiogenic shock and patients with chronic heart failure deteriorating to shock.

Zubair Shah, MD, explains how his research revealed improved outcomes in patients with cardiogenic shock receiving right heart catheterization.

Federico Pappalardo, MD, describes the role of IABP in the treatment of acute-on-chronic heart failure complicated by cardiogenic shock. 

Adam Gottula, MD, discusses considerations for optimizing patient care when transporting patients supported with Impella or other mechanical circulatory support devices.

Chuck Simonton, MD, discusses the limitations of published papers that use administrative or payer databases as data sources and provides an AMI cardiogenic shock example.

Michael Galvin, BS, RDCS, discusses the role of echocardiography and Impella in cardiogenic shock.

Alexandra Lansky, MD, discusses a propensity-adjusted population-based analysis of Impella in patients undergoing high-risk PCI from a large-scale claims dataset. 

Adam Salisbury, MD, presents the primary results from the OPTIMUM Registry, a late breaker at TCT 2021.

Srihari Naidu, MD discusses updates to the SCAI shock stages at TCT 2021.

William O’Neill, MD, discusses the development of best practices for treating AMI cardiogenic shock leading to the RECOVER IV RCT.

Gregg Stone, MD, reviews evidence for the use of mechanical circulatory support during high-risk PCI and provides an overview of the PROTECT IV RCT.

Jason Wollmuth, MD, discusses large-bore access and intravascular imaging best practices for treating high-risk PCI patients.

Jeffrey Moses, MD, discusses the improved outcomes with contemporary practices seen in the PROTECT III study of Impella-supported high-risk PCI.